Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8UKX

Crystal structure the extracellular region of the epidermal growth factor receptor variant III (EGFRvIII) at pH 7.0

Summary for 8UKX
Entry DOI10.2210/pdb8ukx/pdb
Related8UKV 8UKW
DescriptorEpidermal growth factor receptor, alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
Functional Keywordscell surface receptor, glycoprotein, extracellular, glioblastoma, oncogenic variant, transferase
Biological sourceHomo sapiens (human)
More
Total number of polymer chains1
Total formula weight40020.23
Authors
Stayrook, S.E.,Ferguson, K.M. (deposition date: 2023-10-15, release date: 2024-06-12, Last modification date: 2024-10-09)
Primary citationBagchi, A.,Stayrook, S.E.,Xenaki, K.T.,Starbird, C.A.,Doulkeridou, S.,El Khoulati, R.,Roovers, R.C.,Schmitz, K.R.,van Bergen En Henegouwen, P.M.P.,Ferguson, K.M.
Structural insights into the role and targeting of EGFRvIII.
Structure, 32:1367-, 2024
Cited by
PubMed Abstract: The epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung and other cancers. In glioblastoma multiforme (GBM), the EGFR deletion variant III (EGFRvIII) is frequently found alongside EGFR amplification. Agents targeting the EGFR axis have shown limited clinical benefits in GBM and the role of EGFRvIII in GBM is poorly understood. To shed light on the role of EGFRvIII and its potential as a therapeutic target, we determined X-ray crystal structures of a monomeric EGFRvIII extracellular region (ECR). The EGFRvIII ECR resembles the unliganded conformation of EGFR, including the orientation of the C-terminal region of domain II. Domain II is mostly disordered, but the ECR structure is compact. We selected a nanobody with preferential binding to EGFRvIII relative to EGFR and structurally defined an epitope on domain IV that is occluded in the unliganded intact EGFR. These findings suggest new avenues for EGFRvIII targeting in GBM.
PubMed: 38908376
DOI: 10.1016/j.str.2024.05.018
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.301 Å)
Structure validation

236963

PDB entries from 2025-06-04

PDB statisticsPDBj update infoContact PDBjnumon